179 related articles for article (PubMed ID: 37927116)
1. Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
Zelin E; Mazzoletti V; Cavallo F; Nardello C; Corio A; Toffoli L; Tagliaferri L; Conforti C; Di Meo N; Zalaudek I
Australas J Dermatol; 2024 Mar; 65(2):103-113. PubMed ID: 37927116
[TBL] [Abstract][Full Text] [Related]
2. Real-Life Experience with Sonidegib for Locally Advanced Basosquamous Carcinoma: A Case Series.
Bocchino E; Cappilli S; Palmisano G; Paradisi A; Piccerillo A; Di Stefani A; Peris K
Case Rep Dermatol; 2024; 16(1):1-7. PubMed ID: 38178864
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series.
Weissman JP; Samlowski W; Meoz R
Oncologist; 2021 Dec; 26(12):e2247-e2253. PubMed ID: 34472658
[TBL] [Abstract][Full Text] [Related]
4. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced basal cell carcinoma: Real-life data with sonidegib.
Toffoli L; Conforti C; Zelin E; Vezzoni R; Agozzino M; di Meo N; Zalaudek I
Dermatol Ther; 2022 Jun; 35(6):e15441. PubMed ID: 35279921
[TBL] [Abstract][Full Text] [Related]
6. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
[TBL] [Abstract][Full Text] [Related]
7. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
9. Complete response of a large basosquamous carcinoma following treatment with cemiplimab and vismodegib.
Pirruccello J; Afzal MZ; Voudouri M; Shirai K
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37451798
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
Xie P; Lefrançois P
J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
13. Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches.
Murgia G; Denaro N; Boggio F; Nazzaro G; Benzecry V; Bortoluzzi P; Passoni E; Garrone O; Marzano A
Cells; 2023 Nov; 12(23):. PubMed ID: 38067165
[TBL] [Abstract][Full Text] [Related]
14. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced basosquamous carcinoma: Our experience with sonidegib.
Toffoli L; Agozzino M; di Meo N; Zalaudek I; Conforti C
Dermatol Ther; 2022 Jun; 35(6):e15436. PubMed ID: 35278014
[No Abstract] [Full Text] [Related]
17. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M; Chevret S; Grob JJ; Beylot-Barry M; Saiag P; Fléchon A; You B; Maubec E; Jouary T; Toulemonde E; Jamme P; Gambotti L; Lamrani-Ghaouti A; Dupuy A; Lebbe C; Seguin NB; Houede N; Leccia MT; Le Du F; de Pontville M; Gaudy-Marquestre C; Guillot B; Simon C; Marabelle A; Mortier L
Eur J Cancer; 2022 Dec; 177():103-111. PubMed ID: 36335780
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
Lear JT; Morris LM; Ness DB; Lewis LD
Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
[TBL] [Abstract][Full Text] [Related]
20. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
